Founded in 2012, MindMaze is a global leader in brain technology committed to accelerating humanity's ability to recover, learn and adapt. The company operates at the intersection of neuroscience, biosensing, engineering, mixed reality, and artificial intelligence to enhance the recovery potential of patients with neurological diseases.

MindMaze combines FDA cleared and CE marked digital therapeutics with state-of-the-art motion analytics, AI, and cloud technologies to create the universal platform for brain health. Its pioneering solutions focus on neurorehabilitation and brain recovery, delivering a scalable platform adaptable to various clinical and patient needs.

MindMaze Labs, the company's R&D division, extends its groundbreaking neuroscience expertise to everyday life by developing advanced human-machine interfaces powered by brain technology.

MindMaze's commercial digital therapeutics are deployed globally and have transformative impacts on patients and caregivers, addressing neurological conditions such as stroke, Parkinson's, traumatic brain injury (TBI), and mild cognitive impairment (MCI).

MindMaze has a rich history of innovation, including the development of the MindMotion™ GO teleneurorehabilitation platform, FDA and CE certifications, and numerous patents. The company is recognized as the first Swiss unicorn in its sector and has expanded its presence with offices in the US, UK, Germany, and Switzerland.

Its partnerships with leading hospitals and research institutions, ongoing clinical development pipeline, and advanced peripheral technologies such as Izar demonstrate MindMaze's commitment to advancing brain health and neurorehabilitation.